A5036692508- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- CAR-T cell therapy research
- Metastasis and carcinoma case studies
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Cancer Treatment Studies
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroblastoma Research and Treatments
- Renal and related cancers
St Petersburg University
2016-2025
City Clinical Oncology Center
2014-2025
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2023
The University of Texas MD Anderson Cancer Center
2023
AstraZeneca (Brazil)
2023
Clinical Hospital No 122 named after. L.G.Sokolova
2018-2019
Russian Scientific Center of Radiology and Surgical Technologies
2015
Institute of Oncology NN Petrov
2004
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion trial population. This multicenter retrospective cohort assessed real-world safety Len Pembro with clear-cell RCC intermediate or poor International Metastatic Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival...
477 Background: We assessed RAM or MER plus standard of care GEM+CIS as first-line treatment for BTC. Methods: Patients (pts) with BTC, ECOG PS 0/1, and measurable disease were randomized 2:1:2:1 to oral 80 mg QD, PL IV 8 mg/kg days 1 Q3W Q3W. Pts also received up cycles GEM 1000 mg/m 2 + CIS 25 RAM, MER, could continue until progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints: overall (OS), objective response rate (ORR), safety. PFS hazard ratios (HRs)...
Background . Hyperglycemia (HG) is an on-target effect of ALP, and prophylactic with metformin was shown to decrease the rate severity HG. Here we present efficacy safety ALP in a large cohort patients rational approach usage based on risk factors Material Methods Patients (pts) HR+/HeR2- PIK3CA mut ABC were treated 300 mg orally FUL 500 IM until disease progression or intolerance. primary endpoints free survival (PFS) grade 3/4 HG different groups. Pts stratified groups algorithm before...
Введение. В связи с тем, что алгоритм лечения нейроэндокринных опухолей желудочно-кишечного тракта определяется только локализацией неоплазии и ориентирован на классификацию по степени дифференцировки, поиск дополнительных прогностических маркеров является актуальной задачей. Цель. Целью исследования определение факторов неблагоприятного прогноза у пациентов нейроэндокринными опухолями для повышения эффективности лечения. Материалы методы. На начальном этапе проанализированы...
В статье представлены результаты голосования I Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2024», посвященного наиболее актуальным спорным вопросам диагностики, хирургической тактики, лучевой терапии системного лечения данной категории пациентов. Под председательством член-корреспондента РАН, профессора Владимира Федоровича Семиглазова в международном консенсусе приняли участие 38 экспертов области диагностики (РМЖ),...
Immune checkpoint inhibitor-associated myositis is an extremely rare adverse event. However, the high level of mortality, possible combination with other fatal complications, myocarditis, and myasthenia gravis, serve as motivation for active detection treatment myositis. The management patient should involve a neurologist rheumatologist. In most cases, administration glucocorticoids effective. Nevertheless, there currently insufficient data on pathogenesis algorithms steroid-refractory...
Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed death protein 1 (PD-1) or its ligand (PD-L1), are a new generation of immuno-oncological drugs that to date have demonstrated efficacy in number malignancies. The mechanism ICIs action consist the potentiation immune response by eliminating tumor cells inhibitory effect on T-lymphocytes activation. However, excessive system activation can cause development special class...
Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around world, it is extremely important to address issue indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well scope regimens treatment. The article presents results our own study, considers problems toxicity tolerability dose-dense standard NACT regimens. Aim. To study Materials methods. prospective included 109 patients. 53 patients received preoperative treatment, 56 – regimen. Results....
ABSTRACT Background This ambispective study was designed to assess the efficacy and safety of avelumab maintenance in a real‐world population patients with metastatic urothelial cancer (UC). Methods Patients UC measurable disease that had not progressed following first‐line platinum‐based chemotherapy were treated (800 mg administered every 2 weeks). The primary endpoint overall survival (OS). Results A total 110 enrolled. majority male (81%), median age 65 years (range, 36–84). OS reached,...
Введение. Развитие микросателлитной нестабильности в результате герминативной или спорадической мутации генах системы репарации ошибочно спаренных нуклеотидов (MMR) является ключевым звеном запуске механизмов канцерогенеза посредством формирования опухолевых неоантигенов, представляющих собой мишени для Т-лимфоцитов, что, конечном счете, обусловливает высокую иммуногенность данных опухолей и их чувствительность к ингибиторам контрольных точек иммунитета. Цель. Определение...
Studies of drugs from the group cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as first-line therapy are currently not limited to patients with metastatic luminal Her2-negative (ER+/HER2-) breast cancer. A number preclinical and clinical studies have demonstrated potential CDK4/6 in treatment HER2-positive cancer positive expression hormone receptors («triple-positive» subtype). However, these studies, were used together monoclonal antibodies (Trastuzumab, Pertuzumab). This article presents...
Neuroendocrine tumors (NETs) include heterogeneous neoplasms that can be functional or symptomatically active (functioning) non-functioning. The overall incidence of NETs is growing faster than the all human malignancies. are second most common gastrointestinal cancers, characterized by frequent liver metastasis, which a major factor affecting quality life and significant survival patients. Cytoreductive treatment metastases (NELM) method choice aimed at ensuring prolongation patient...
The article presents a clinical case of treatment young man with locally advanced renal cell carcinoma an inferior vena cava tumor thrombus above the diaphragm. Due to non-standard neoadjuvant approach using modern tyrosine kinase inhibitors VEGFR and immunotherapy (VEGFR-TKI/IO) combination pembrolizumab + lenvatinib, thoracotomy was avoided complete pathological regression achieved. Various studies on therapy kidney cancer including in patients are discussed, prospects for introducing this...
Elenagen is a plasmid encoding p62/SQSTM1, the first DNA vaccine possessing two mutually complementing mechanisms of action: it elicits immune response against p62 and mitigates systemic chronic inflammation. Previously, demonstrated anti-tumor efficacy safety in rodent tumor models spontaneous tumors dogs. This multicenter I/IIa trial evaluated clinical activity patients with advanced solid tumors. Fifteen were treated escalating doses (1- 5 mg per doses, times weekly) additional 12...
Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response survival rates. However, real-world data on treatment patterns clinical outcomes patients with BRAF V600 mutant are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 melanoma, who received TT a setting were not involved trials. collected from twelve medical centers Russia. objective...
Gastrointestinal stromal tumors (GIST) comprise about 80% of gastrointestinal sarcomas. In patients with localized disease, surgery is considered as "Gold Standard" treatment. Organ-sparing radical en-block resection widely accepted practice. Since lymph node dissection not routinely indicated, minimally invasive approach particular interest. The aim this study to investigate the short-term outcomes different surgical treatment GISTs.We analyzed data 116 who received for forms GIST. Tumors...